Index - 2021

adverse effects authorisation 20215-7 pharmaco-epidemiological research 20215-7 prevention 20215-7 vaccines 20215-7 amisulpride antipsychotics 202121-28 schizophrenia 202121-28 antipsychotics amisulpride 202121-28 schizophrenia 202121-28 arrhythmia atrial fibrillation 202117-20 medical app 202117-20 medical device 202117-20 smartwatch app 202117-20 AstraZeneca Vaxzevria® 202129-34 covid-19 202129-34 ema 202129-34 mutation 202129-34 pandemic 202129-34 vaccines 202129-34 vector vaccine 202129-34 atrial fibrillation arrhythmia 202117-20 medical app 202117-20 medical device 202117-20 smartwatch app 202117-20 authorisation adverse effects 20215-7 pharmaco-epidemiological research 20215-7 prevention 20215-7 vaccines 20215-7 bivalent vaccine HPV 202147-56 carcinoma 202147-56 cervical 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56 carcinoma HPV 202147-56 bivalent vaccine 202147-56 cervical 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56 cardiovascular glucose 202141-46 interventions 202141-46 level 202141-46 lifestyle 202141-46 renal 202141-46 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46 cardiovascular problem LDL-cholesterol 20211-4 TIA 20211-4 cerebral infarction 20211-4 prevention 20211-4 cerebral infarction LDL-cholesterol 20211-4 TIA 20211-4 cardiovascular problem 20211-4 prevention 20211-4 cervical HPV 202147-56 bivalent vaccine 202147-56 carcinoma 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56 clopidogrel CYP2C19-genotyping 20219-12 PCI 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 covid-19 AstraZeneca 202129-34 Vaxzevria® 202129-34 ema 202129-34 mutation 202129-34 pandemic 202129-34 vaccines 202129-34 vector vaccine 202129-34 CYP2C19-genotyping PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 egfr tyrokinase inhibitor Erlotinib 202135-40 non-small-cell lung carcinoma 202135-40 progression-free survival 202135-40 ema AstraZeneca 202129-34 Vaxzevria® 202129-34 covid-19 202129-34 mutation 202129-34 pandemic 202129-34 vaccines 202129-34 vector vaccine 202129-34 Erlotinib egfr tyrokinase inhibitor 202135-40 non-small-cell lung carcinoma 202135-40 progression-free survival 202135-40 glucose cardiovascular 202141-46 interventions 202141-46 level 202141-46 lifestyle 202141-46 renal 202141-46 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46 HPV bivalent vaccine 202147-56 carcinoma 202147-56 cervical 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56 human papilloma virus HPV 202147-56 bivalent vaccine 202147-56 carcinoma 202147-56 cervical 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56 interventions cardiovascular 202141-46 glucose 202141-46 level 202141-46 lifestyle 202141-46 renal 202141-46 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46 LDL-cholesterol TIA 20211-4 cardiovascular problem 20211-4 cerebral infarction 20211-4 prevention 20211-4 level cardiovascular 202141-46 glucose 202141-46 interventions 202141-46 lifestyle 202141-46 renal 202141-46 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46 lifestyle cardiovascular 202141-46 glucose 202141-46 interventions 202141-46 level 202141-46 renal 202141-46 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46 medical app arrhythmia 202117-20 atrial fibrillation 202117-20 medical device 202117-20 smartwatch app 202117-20 medical device arrhythmia 202117-20 atrial fibrillation 202117-20 medical app 202117-20 smartwatch app 202117-20 mRNA-vaccin SARS-CoV-2 202113-16 mutation AstraZeneca 202129-34 Vaxzevria® 202129-34 covid-19 202129-34 ema 202129-34 pandemic 202129-34 vaccines 202129-34 vector vaccine 202129-34 non-small-cell lung carcinoma Erlotinib 202135-40 egfr tyrokinase inhibitor 202135-40 progression-free survival 202135-40 nonavalent vaccine HPV 202147-56 bivalent vaccine 202147-56 carcinoma 202147-56 cervical 202147-56 human papilloma virus 202147-56 quadrivalent vaccine 202147-56 vaccination programme 202147-56 pandemic AstraZeneca 202129-34 Vaxzevria® 202129-34 covid-19 202129-34 ema 202129-34 mutation 202129-34 vaccines 202129-34 vector vaccine 202129-34 PCI CYP2C19-genotyping 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 percutaneous coronary intervention CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 pharmaco-epidemiological research adverse effects 20215-7 authorisation 20215-7 prevention 20215-7 vaccines 20215-7 poor metabolizers CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 prasugrel CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 prevention LDL-cholesterol 20211-4 TIA 20211-4 adverse effects 20215-7 authorisation 20215-7 cardiovascular problem 20211-4 cerebral infarction 20211-4 pharmaco-epidemiological research 20215-7 vaccines 20215-7 progression-free survival Erlotinib 202135-40 egfr tyrokinase inhibitor 202135-40 non-small-cell lung carcinoma 202135-40 quadrivalent vaccine HPV 202147-56 bivalent vaccine 202147-56 carcinoma 202147-56 cervical 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 vaccination programme 202147-56 renal cardiovascular 202141-46 glucose 202141-46 interventions 202141-46 level 202141-46 lifestyle 202141-46 sglt-2 inhibitors 202141-46 type 2 diabetes mellitus 202141-46 SARS-CoV-2 mRNA-vaccin 202113-16 schizophrenia amisulpride 202121-28 antipsychotics 202121-28 sglt-2 inhibitors cardiovascular 202141-46 glucose 202141-46 interventions 202141-46 level 202141-46 lifestyle 202141-46 renal 202141-46 type 2 diabetes mellitus 202141-46 smartwatch app arrhythmia 202117-20 atrial fibrillation 202117-20 medical app 202117-20 medical device 202117-20 stent CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 thrombosis prophylaxis 20219-12 ticagrelor 20219-12 thrombosis prophylaxis CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 ticagrelor 20219-12 TIA LDL-cholesterol 20211-4 cardiovascular problem 20211-4 cerebral infarction 20211-4 prevention 20211-4 ticagrelor CYP2C19-genotyping 20219-12 PCI 20219-12 clopidogrel 20219-12 percutaneous coronary intervention 20219-12 poor metabolizers 20219-12 prasugrel 20219-12 stent 20219-12 thrombosis prophylaxis 20219-12 type 2 diabetes mellitus cardiovascular 202141-46 glucose 202141-46 interventions 202141-46 level 202141-46 lifestyle 202141-46 renal 202141-46 sglt-2 inhibitors 202141-46 vaccination programme HPV 202147-56 bivalent vaccine 202147-56 carcinoma 202147-56 cervical 202147-56 human papilloma virus 202147-56 nonavalent vaccine 202147-56 quadrivalent vaccine 202147-56 vaccines AstraZeneca 202129-34 Vaxzevria® 202129-34 adverse effects 20215-7 authorisation 20215-7 covid-19 202129-34 ema 202129-34 mutation 202129-34 pandemic 202129-34 pharmaco-epidemiological research 20215-7 prevention 20215-7 vector vaccine 202129-34 Vaxzevria® AstraZeneca 202129-34 covid-19 202129-34 ema 202129-34 mutation 202129-34 pandemic 202129-34 vaccines 202129-34 vector vaccine 202129-34 vector vaccine AstraZeneca 202129-34 Vaxzevria® 202129-34 covid-19 202129-34 ema 202129-34 mutation 202129-34 pandemic 202129-34 vaccines 202129-34